This study is looking at how the diabetes medication Pioglitazone affects people with type 2 diabetes, obesity, and a specific type of heart failure called heart failure with preserved ejection fraction (HFpEF). Researchers want to see if Pioglitazone can improve how well your heart pumps blood (systolic and diastolic function). You would take Pioglitazone or a placebo (an inactive pill) once a day for 24 weeks. To join, you should be between 30 and 70 years old, have a BMI between 27.5 and 40 kg/m², and have an HbA1c (a measure of blood sugar) between 6.5% and 10%. Your kidney function (eGFR) also needs to be greater than 45 ml/min/1.73m². The study plans to enroll 78 participants.

Study design

This is an interventional study where participants will be randomly assigned to receive either Pioglitazone or a placebo. It plans to enroll 78 participants.

What's involved

Participants will take tablets once a day for 24 weeks. Heart function will be measured at the beginning of the study and again after 6 months.

Compensation

Not stated in the trial record.

Follow-up

Heart function will be measured at 6 months post-treatment, which is approximately 24 weeks after starting the intervention.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.